Top 5 Drug Type | Count |
---|---|
Small molecule drug | 9 |
Target |
Mechanism UL30 inhibitors [+1] |
Active Org. |
Originator Org. |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date04 Jun 2021 |
Target |
Mechanism CXCR4 antagonists [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Mechanism Akt-1 inhibitors [+3] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Apr 2024 |
Sponsor / Collaborator |
Start Date16 Aug 2023 |
Sponsor / Collaborator |
Start Date14 Feb 2023 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Brincidofovir ( UL30 x UL54 ) | Smallpox More | Approved |
Dordaviprone ( Akt-1 x D2 receptor x ERK1 x ERK2 ) | Diffuse midline glioma, point mutation K27M in histone H3 More | Phase 3 |
Dociparstat sodium ( CXCR4 x SDF-1 ) | Acute Myeloid Leukemia More | Phase 3 |
Tenofovir Exalidex ( RT ) | Hepatitis B More | Phase 2 |
ONC-206 ( CLPP x D2 receptor x D3 receptor ) | Pinealoma More | Phase 1 |